No, the rationale is to provide effective care. The example perhaps you're looking at is our policy with respect to proton pump inhibitors, and when we introduced that, we looked carefully at the literature. We saw that based on the studies within that class of proton pump inhibitors, there were a variety of different products that had by and large the same therapeutic effect.
